The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•13 April 2026•

1 min read

AilsynBio and Dong-E-E-Jiao Partner to Modernize Traditional Medicine via AI

Key Facts

1AilsynBio and Dong-E-E-Jiao signed an innovative project cooperation agreement.

2The collaboration aims to integrate AI technologies into the development of Traditional Chinese Medicine (TCM).

AilsynBio and Dong-E-E-Jiao have officially signed a cooperation agreement to launch an innovative project aimed at transforming the traditional medicine landscape. The partnership focuses on integrating advanced Artificial Intelligence (AI) technologies into the research and development of Traditional Chinese Medicine (TCM). By leveraging AilsynBio's AI-driven drug discovery platform, the collaboration seeks to accelerate the identification of active compounds and enhance product efficacy. Dong-E-E-Jiao aims to modernize its product pipeline and drive innovation within the broader health industry through this digital transformation. Analysts view this move as a strategic step toward combining ancient medical wisdom with cutting-edge computational science. The initiative is expected to strengthen Dong-E-E-Jiao's competitive position in the biotech sector over the long term.